Souhaitez-vous accéder aux communiqués récents ?

Transaction is Hopewell’s first commercial license of proprietary lipid nanoparticles (LNPs)Hopewell’s LNPs are the preferred delivery solution for the cancer vaccine technology that Foxcroft licensed...

NEW YORK, March 05, 2026 (GLOBE NEWSWIRE) -- Wacoal, the nation’s leading designer intimate apparel brand, today announced its Spring 2026 Fit for the Cure® events in partnership with Susan G....

OCALA, Fla., March 04, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) – AIM ImmunoTech Inc. (“AIM” or the “Company”), an immuno-pharma company focused on the research and...

Fort Wayne Medical Oncology and Hematology and Cameron Health Partner to Increase Access to Community Cancer Care in Angola, Indiana

EDAP to Announce Fourth Quarter and Full Year 2025 Financial Results on March 25, 2026 Company to host conference call and webcast on Wednesday, March 25 at 8:30 a.m. EDT AUSTIN, Texas, March 4,...

Ramat Gan, Israel, March 04, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a clinical-stage biotechnology company developing a pipeline of proprietary small...

Nationwide media tour conducted by Wacoal, in conjunction with D S Simon Media, discussing Fit for the Cure® Celebrates 25 Years: Wacoal hosts 400+ nationwide events supporting Susan G. Komen’s direct...

Preclinical data shines: >85% tumor growth inhibition in pancreatic models, reduced fibrosis and resistance markers, and a gentler safety profile

OCALA, Fla., March 02, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced an agreement with the PPD™ clinical research business of Thermo...

OCALA, Fla., Feb. 27, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) – AIM ImmunoTech Inc. (“AIM” or the “Company”), an immuno-pharma company focused on the research and...